257 related articles for article (PubMed ID: 12908351)
21. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
[TBL] [Abstract][Full Text] [Related]
22. Inflixmab as a possible treatment for the hemorrhagic type of Crohn's disease.
Tsujikawa T; Nezu R; Andoh A; Saotome T; Araki Y; Ishizuka Y; Sasaki M; Koyama S; Fujiyama Y
J Gastroenterol; 2004; 39(3):284-7. PubMed ID: 15065007
[TBL] [Abstract][Full Text] [Related]
23. Granular cell tumour in a patient with Crohn's disease treated with infliximab: coincidence or causal relationship?
Papamichael K; Archavlis E; Lariou C; Tsigka A; Mantzaris GJ
Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):857-9. PubMed ID: 22475791
[TBL] [Abstract][Full Text] [Related]
24. Crohn's colitis presenting with node-negative colon cancer and liver metastasis after therapy with infliximab: report of two cases.
Nicholson T; Orangio GR; Brandenburg D; Wolf DC; Pennington EE
Dis Colon Rectum; 2005 Aug; 48(8):1651-5. PubMed ID: 15933793
[No Abstract] [Full Text] [Related]
25. Does administration of infliximab increase susceptibility to listeriosis?
Morelli J; Wilson FA
Am J Gastroenterol; 2000 Mar; 95(3):841-2. PubMed ID: 10710107
[No Abstract] [Full Text] [Related]
26. Treatment of vulval Crohn's disease with infliximab.
Preston PW; Hudson N; Lewis FM
Clin Exp Dermatol; 2006 May; 31(3):378-80. PubMed ID: 16681581
[TBL] [Abstract][Full Text] [Related]
27. [Increased risk of infection with biological immunomodifying antirheumatic agents. Clear guidelines are necessary as shown by case reports].
Söderlin M; Blomkvist C; Dahl P; Forsberg P; Fohlman J
Lakartidningen; 2005 Dec 5-11; 102(49):3794-6, 3799-800. PubMed ID: 16408703
[TBL] [Abstract][Full Text] [Related]
28. Listeria monocytogenes sepsis in patients treated with anti-tumor necrosis factor-alpha.
Tweezer-Zaks N; Shiloach E; Spivak A; Rapoport M; Novis B; Langevitz P
Isr Med Assoc J; 2003 Nov; 5(11):829-30. PubMed ID: 14650115
[No Abstract] [Full Text] [Related]
29. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
30. Guidelines for treatment with infliximab for Crohn's disease.
Hommes DW; Oldenburg B; van Bodegraven AA; van Hogezand RA; de Jong DJ; Romberg-Camps MJ; van der Woude J; Dijkstra G;
Neth J Med; 2006; 64(7):219-29. PubMed ID: 16929083
[TBL] [Abstract][Full Text] [Related]
31. [What can be expected from biological therapies for Crohn's disease?].
Lemann M
Gastroenterol Clin Biol; 2001 Nov; 25(11):945-7. PubMed ID: 11845043
[No Abstract] [Full Text] [Related]
32. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study.
Ryan BM; Russel MG; Schurgers L; Wichers M; Sijbrandij J; Stockbrugger RW; Schoon E
Aliment Pharmacol Ther; 2004 Oct; 20(8):851-7. PubMed ID: 15479356
[TBL] [Abstract][Full Text] [Related]
33. [Opportunistic co-infection in a patient with Crohn's disease during infliximab (anti-TNFalpha) therapy].
Salavert M; Bastida G; Pemán J; Nos P
Rev Iberoam Micol; 2009 Sep; 26(3):213-7. PubMed ID: 19635442
[TBL] [Abstract][Full Text] [Related]
34. [Meningitis due to Listeria monocytogenes as a complication of infliximab therapy].
Keulen ET; Mebis J; Erdkamp FL; Peters FP
Ned Tijdschr Geneeskd; 2003 Oct; 147(43):2145. PubMed ID: 14619208
[No Abstract] [Full Text] [Related]
35. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
[TBL] [Abstract][Full Text] [Related]
36. Re: Triantafillidis et al.--Acute idiopathic pancreatitis complicating active Crohn's disease: favorable response to infliximab treatment.
Fefferman DS; Alsahli M; Lodhavia PJ; Shah SA; Farrell RJ
Am J Gastroenterol; 2001 Aug; 96(8):2510-1. PubMed ID: 11513207
[No Abstract] [Full Text] [Related]
37. [Meningitis due to Listeria monocytogenes during adalimumab therapy].
Gil C; Legido J; Cuenca C; Santamaría A; Sacristán MV; Salvatierra C; Fernández-Rubio E; Izquierdo J
Gastroenterol Hepatol; 2009 Oct; 32(8):587-8. PubMed ID: 19525035
[No Abstract] [Full Text] [Related]
38. Tuberculosis and treatment with infliximab.
Zhang Z; Correa H; Bégué RE
N Engl J Med; 2002 Feb; 346(8):623-6. PubMed ID: 11859880
[No Abstract] [Full Text] [Related]
39. Complications of infliximab therapy in children and adolescents affected by Crohn's disease.
Diamanti A; Papadatou B; Knafelz D; Gambarara M; Ferretti F; Castro M
Am J Gastroenterol; 2003 Dec; 98(12):2812-3. PubMed ID: 14687847
[No Abstract] [Full Text] [Related]
40. Anorectal carcinoma after infliximab therapy in Crohn's disease: report of a case.
Melichar B; Bures J; Dedic K
Dis Colon Rectum; 2006 Aug; 49(8):1228-33. PubMed ID: 16845561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
